Su et al. found that anlotinib reactivates the immune microenvironment and relies on CD4+ T-cell to promote the normalization of tumor blood vessels; therefore, the combination of anlotinib and ICIs can enhance treatment efficacy (Su et al., 2022). This evidence concerns the gene CD4 and neoplasm.